SG11201806424TA - Therapeutic compounds - Google Patents
Therapeutic compoundsInfo
- Publication number
- SG11201806424TA SG11201806424TA SG11201806424TA SG11201806424TA SG11201806424TA SG 11201806424T A SG11201806424T A SG 11201806424TA SG 11201806424T A SG11201806424T A SG 11201806424TA SG 11201806424T A SG11201806424T A SG 11201806424TA SG 11201806424T A SG11201806424T A SG 11201806424TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- manchester
- compounds
- pct
- street
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/129829 Al 3 August 2017 (03.08.2017) WIPO I PCT 11111111111111011101111111111101011111011101110111111111010111110111111111110111111 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) (51) International Patent Classification: CO7D 401/14 (2006.01) A61P 3/04 (2006.01) A61K 31/506 (2006.01) A61P 25/00 (2006.01) A61K 31/497 (2006.01) (21) International Application Number: PCT/EP2017/051960 (22) International Filing Date: 30 January 2017 (30.01.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1601703.0 29 January 2016 (29.01.2016) GB (71) Applicant: C4X DISCOVERY LIMITED [GB/GB]; Manchester One, Suite 4B, 53 Portland Street, Manchester Ml 3LD (GB). (72) Inventor: MARTIN, Barrie; C4X Discovery Limited, Manchester One, Suite 4B, 53 Portland Street, Manchester Ml 3LD (GB). (74) Agent: HGF LIMITED; 4th Floor Merchant Exchange, 17-19 Whitworth Street West, Manchester Ml 5WG (GB). — (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, = (54) Title: THERAPEUTIC COMPOUNDS N N N H N N N N X N s, X2 C F3 (I) (57) : The present invention relates to compounds that are antagonists of the orexin-1 receptor. The compounds have the structural formula (I) defined herein. The present invention also relates to processes for the preparation of these compounds, to phar - maceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with orexin-1 receptor activity. 0 W O 20 17 / 1298 29 Al
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1601703.0A GB201601703D0 (en) | 2016-01-29 | 2016-01-29 | Therapeutic compounds |
| PCT/EP2017/051960 WO2017129829A1 (en) | 2016-01-29 | 2017-01-30 | Therapeutic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201806424TA true SG11201806424TA (en) | 2018-08-30 |
Family
ID=55590433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201806424TA SG11201806424TA (en) | 2016-01-29 | 2017-01-30 | Therapeutic compounds |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US10696654B2 (en) |
| EP (1) | EP3408265B1 (en) |
| JP (1) | JP6898933B2 (en) |
| KR (2) | KR20250073547A (en) |
| CN (1) | CN108779098B (en) |
| AU (1) | AU2017213177B2 (en) |
| CA (1) | CA3012408C (en) |
| DK (1) | DK3408265T3 (en) |
| EA (1) | EA035188B1 (en) |
| ES (1) | ES2794622T3 (en) |
| GB (1) | GB201601703D0 (en) |
| IL (1) | IL260720B (en) |
| MY (1) | MY201535A (en) |
| SG (1) | SG11201806424TA (en) |
| WO (1) | WO2017129829A1 (en) |
| ZA (1) | ZA201805046B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2491038T (en) | 2009-10-23 | 2016-07-14 | Janssen Pharmaceutica Nv | Disubstituted octahy - dropyrrolo [3,4-c]pyrroles as orexin receptor modulators |
| GB201415569D0 (en) | 2014-09-03 | 2014-10-15 | C4X Discovery Ltd | Therapeutic Compounds |
| GB201601703D0 (en) * | 2016-01-29 | 2016-03-16 | C4X Discovery Ltd | Therapeutic compounds |
| EA201891930A1 (en) | 2016-03-10 | 2019-02-28 | Янссен Фармацевтика Нв | METHODS OF TREATING DEPRESSION USING ANTAGONISTS OF OREXIN RECEPTORS-2 |
| CA3074059A1 (en) | 2017-09-01 | 2019-03-07 | Chronos Therapeutics Limited | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists |
| WO2019063605A1 (en) | 2017-09-28 | 2019-04-04 | Boehringer Ingelheim International Gmbh | Novel n-(2,2-difluoroethyl)-n-[(pyrimidinylamino)propanyl]arylcarboxamides |
| GB201901142D0 (en) | 2019-01-28 | 2019-03-20 | Heptares Therapeutics Ltd | OX1 Antagonists |
| GB202311280D0 (en) | 2023-07-21 | 2023-09-06 | Bial Portela & Ca Sa | Orexin receptor antagonists |
| GB202311281D0 (en) | 2023-07-21 | 2023-09-06 | Bial Portela & Ca Sa | Orexin receptor antagonists |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB240685A (en) | 1924-12-24 | 1925-10-08 | Donald Garvie | Improvements in one-way driving mechanism |
| US5968965A (en) | 1996-01-30 | 1999-10-19 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| WO1997027852A1 (en) | 1996-01-30 | 1997-08-07 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6861448B2 (en) | 1998-01-14 | 2005-03-01 | Virtual Drug Development, Inc. | NAD synthetase inhibitors and uses thereof |
| GB9930557D0 (en) | 1999-12-23 | 2000-02-16 | Rolic Ag | Optically active materials |
| WO2001077091A2 (en) | 2000-04-05 | 2001-10-18 | Tularik Inc. | Ns5b hcv polymerase inhibitors |
| DE10027151A1 (en) | 2000-05-31 | 2001-12-06 | Bayer Ag | Herbicides based on substituted carboxamides |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| JP2002326980A (en) | 2001-04-27 | 2002-11-15 | Nippon Nohyaku Co Ltd | Diamide derivatives, agricultural and horticultural agents and methods of using the same |
| JP2003012625A (en) | 2001-06-28 | 2003-01-15 | Dainippon Ink & Chem Inc | Amide derivatives and pesticides |
| JP2005509594A (en) | 2001-07-13 | 2005-04-14 | バーチャル ドラッグ ディヴェロップメント、インコーポレイティッド | NAD synthetase inhibitors and uses thereof |
| GB0130341D0 (en) * | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| US20040266732A1 (en) | 2002-09-20 | 2004-12-30 | Jorge Galvez | Therapeutic agents, methods, and treatments |
| US7250415B2 (en) | 2003-06-04 | 2007-07-31 | Bristol-Myers Squibb Company | 1,1-Disubstitutedcycloalkyl-, glycinamidyl-, sulfonyl-amidino-, and tetrahydropyrimidinyl-containing diaminoalkyl, β-aminoacids, α-aminoacids and derivatives thereof as factor Xa inhibitors |
| EP1637521B1 (en) | 2003-06-23 | 2013-06-19 | Ono Pharmaceutical Co., Ltd. | Novel tricyclic heterocycle compound |
| US7459472B2 (en) | 2003-08-08 | 2008-12-02 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| JP2007501844A (en) | 2003-08-08 | 2007-02-01 | トランス テック ファーマ，インコーポレイテッド | Aryl and heteroaryl compounds, compositions and methods of use |
| EP1685109A2 (en) | 2003-10-07 | 2006-08-02 | Renovis, Inc. | Amide compounds as ion channel ligands and uses thereof |
| US7517900B2 (en) | 2003-10-10 | 2009-04-14 | Bristol-Myers Squibb Company | Pyrazole derivatives as cannabinoid receptor modulators |
| US20080249154A1 (en) | 2003-12-26 | 2008-10-09 | Ono Pharmaceutical Co., Ltd. | Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates |
| EP1732925A1 (en) | 2004-03-17 | 2006-12-20 | Altana Pharma AG | Novel n-(alkoxyalkyl)carbamoyl- substituted 6-phenyl-benzonaphthyridine derivatives and their use as pde3/4 inhibitors |
| EP1736465A4 (en) | 2004-03-31 | 2009-06-17 | Ajinomoto Kk | Aniline derivatives |
| EP1758883B1 (en) | 2004-05-18 | 2011-11-02 | Schering Corporation | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors |
| WO2006001463A1 (en) | 2004-06-23 | 2006-01-05 | Ono Pharmaceutical Co., Ltd. | Compound having s1p receptor binding potency and use thereof |
| WO2006038594A1 (en) | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | N-type calcium channel inhibitor |
| WO2006099379A2 (en) | 2005-03-14 | 2006-09-21 | Transtech Pharma, Inc. | Benzazole derivatives, compositions, and methods of use as b-secretase inhibitors |
| US20080262046A1 (en) | 2005-04-12 | 2008-10-23 | Coleman Paul J | Amidopropoxyphenyl Orexin Receptor Antagonists |
| UY30118A1 (en) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | AMIS TRISUSTITUDE COMPUTER |
| US20090105318A1 (en) | 2006-03-29 | 2009-04-23 | Coleman Paul J | Amidoethylthioether Orexin Receptor Antagonists |
| WO2008002671A2 (en) | 2006-06-29 | 2008-01-03 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors |
| GB0623258D0 (en) | 2006-11-22 | 2007-01-03 | Remynd Nv | Thiadiazole derivatives for the treatment of neuro-degenerative diseases |
| JP4785881B2 (en) | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | Medicine |
| WO2009011775A1 (en) | 2007-07-13 | 2009-01-22 | Merck & Co., Inc. | Amidoethyl alkylamino orexin receptor antagonists |
| RU2010106393A (en) | 2007-07-26 | 2011-09-10 | Зингента Партисипейшнс Аг (Ch) | NEW MICROBIOCIDES |
| US20110263662A1 (en) | 2007-08-15 | 2011-10-27 | Hamed Aissaoui | 1,2-diamido-ethylene derivatives as orexin antagonists |
| BRPI0911814A2 (en) | 2008-08-01 | 2018-05-29 | Bayer Cropscience Ag | "Compound, fungicidal composition and method for control of crop phytopathogenic fungus" |
| WO2010086366A1 (en) | 2009-01-30 | 2010-08-05 | Novartis Ag | 4-aryl-butane-1,3-diamides |
| US9212177B2 (en) | 2009-08-05 | 2015-12-15 | Versitech Limited | Antiviral compounds and methods of making and using thereof |
| KR20120092567A (en) | 2009-08-05 | 2012-08-21 | 벌시테크 리미티드 | Antiviral compounds and methods of making and using thereof cross reference to related applications |
| WO2011073316A1 (en) | 2009-12-18 | 2011-06-23 | Novartis Ag | 4-aryl-butane-1,3-diamides |
| CN106107406B (en) | 2010-08-12 | 2020-06-09 | 弗门尼舍公司 | Methods of improving the stability of sweetness enhancers and compositions comprising stable sweetness enhancers |
| JP5570921B2 (en) | 2010-09-08 | 2014-08-13 | アグロカネショウ株式会社 | N-phenylthioalkylpyrazole-3-carboxamide derivative and acaricide containing the derivative as an active ingredient |
| EP2655334B1 (en) | 2010-12-22 | 2018-10-03 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
| US9321727B2 (en) | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| EP2532661A1 (en) | 2011-06-10 | 2012-12-12 | Syngenta Participations AG | Novel insecticides |
| US8946430B2 (en) | 2011-09-30 | 2015-02-03 | Bristol-Myers Squibb Company | Quinolinone carboxamide inhibitors of endothelial lipase |
| WO2013066833A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods to inhibit histone deacetylase (hdac) enzymes |
| CN104203223A (en) | 2011-11-25 | 2014-12-10 | 拜耳知识产权有限责任公司 | Use of aryl and hetaryl carboxamides as endoparasiticides |
| JP5830821B2 (en) | 2012-04-11 | 2015-12-09 | アグロカネショウ株式会社 | N-thioalkylpyrazole-3-carboxamide derivatives and acaricides containing the same as active ingredients |
| WO2013158928A2 (en) | 2012-04-18 | 2013-10-24 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
| NZ702635A (en) * | 2012-06-15 | 2016-11-25 | Taisho Pharmaceutical Co Ltd | Branched chain alkyl heteroaromatic ring derivative |
| AU2013310074B2 (en) | 2012-08-30 | 2018-07-05 | Nihon Nohyaku Co., Ltd. | Endoparasite control agent |
| IN2015MN00404A (en) | 2012-08-30 | 2015-09-04 | Univ Tokyo | |
| HRP20170628T1 (en) | 2012-09-21 | 2017-06-30 | Sanofi | BENZOIMIDAZOL-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC OR CARDIOVASCULAR DISEASES |
| EP2730570A1 (en) | 2012-11-13 | 2014-05-14 | Bayer CropScience AG | Pyridyloxyal alkyl carboxamides and their use as endoparasiticides and nematicide |
| TW201444849A (en) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | Substituted 7-azabicycles and their use as orexin receptor modulators |
| TW201444821A (en) * | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | Substituted piperidine compounds and their use as orexin receptor modulators |
| WO2015123355A1 (en) * | 2014-02-12 | 2015-08-20 | Eolas Therapeutics, Inc. | Substituted prolines / piperidines as orexin receptor antagonists |
| MA39999A (en) | 2014-06-06 | 2015-12-10 | Res Triangle Inst | Apelin receptor (apj) agonists and uses thereof |
| GB201415569D0 (en) * | 2014-09-03 | 2014-10-15 | C4X Discovery Ltd | Therapeutic Compounds |
| WO2016100161A1 (en) | 2014-12-19 | 2016-06-23 | Merck Sharp & Dohme Corp. | Ethyldiamine orexin receptor antagonists |
| GB201601703D0 (en) | 2016-01-29 | 2016-03-16 | C4X Discovery Ltd | Therapeutic compounds |
-
2016
- 2016-01-29 GB GBGB1601703.0A patent/GB201601703D0/en not_active Ceased
-
2017
- 2017-01-30 CN CN201780012049.0A patent/CN108779098B/en active Active
- 2017-01-30 KR KR1020257015939A patent/KR20250073547A/en active Pending
- 2017-01-30 US US16/073,429 patent/US10696654B2/en active Active
- 2017-01-30 EA EA201891710A patent/EA035188B1/en not_active IP Right Cessation
- 2017-01-30 WO PCT/EP2017/051960 patent/WO2017129829A1/en active Application Filing
- 2017-01-30 JP JP2018539318A patent/JP6898933B2/en active Active
- 2017-01-30 AU AU2017213177A patent/AU2017213177B2/en active Active
- 2017-01-30 ES ES17703085T patent/ES2794622T3/en active Active
- 2017-01-30 CA CA3012408A patent/CA3012408C/en active Active
- 2017-01-30 KR KR1020187024851A patent/KR102810105B1/en active Active
- 2017-01-30 DK DK17703085.5T patent/DK3408265T3/en active
- 2017-01-30 EP EP17703085.5A patent/EP3408265B1/en active Active
- 2017-01-30 SG SG11201806424TA patent/SG11201806424TA/en unknown
- 2017-01-30 MY MYPI2018702606A patent/MY201535A/en unknown
-
2018
- 2018-07-22 IL IL260720A patent/IL260720B/en unknown
- 2018-07-26 ZA ZA2018/05046A patent/ZA201805046B/en unknown
-
2020
- 2020-04-28 US US16/860,572 patent/US11130746B2/en active Active
-
2021
- 2021-08-27 US US17/459,598 patent/US11753398B2/en active Active
-
2023
- 2023-07-25 US US18/225,966 patent/US20240076282A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3012408C (en) | 2023-12-12 |
| KR20250073547A (en) | 2025-05-27 |
| EA201891710A1 (en) | 2019-01-31 |
| CN108779098B (en) | 2021-04-09 |
| US10696654B2 (en) | 2020-06-30 |
| KR20180117627A (en) | 2018-10-29 |
| EA035188B1 (en) | 2020-05-12 |
| IL260720A (en) | 2018-10-31 |
| EP3408265B1 (en) | 2020-05-13 |
| JP6898933B2 (en) | 2021-07-07 |
| US11753398B2 (en) | 2023-09-12 |
| CA3012408A1 (en) | 2017-08-03 |
| EP3408265A1 (en) | 2018-12-05 |
| AU2017213177B2 (en) | 2020-10-08 |
| NZ744982A (en) | 2024-07-05 |
| GB201601703D0 (en) | 2016-03-16 |
| US20200255404A1 (en) | 2020-08-13 |
| IL260720B (en) | 2021-09-30 |
| US20210395227A1 (en) | 2021-12-23 |
| KR102810105B1 (en) | 2025-05-21 |
| WO2017129829A1 (en) | 2017-08-03 |
| US11130746B2 (en) | 2021-09-28 |
| HK1258727A1 (en) | 2019-11-15 |
| US20190040041A1 (en) | 2019-02-07 |
| MY201535A (en) | 2024-02-28 |
| US20240076282A1 (en) | 2024-03-07 |
| NZ783506A (en) | 2024-10-25 |
| ZA201805046B (en) | 2022-03-30 |
| CN108779098A (en) | 2018-11-09 |
| AU2017213177A1 (en) | 2018-08-09 |
| ES2794622T3 (en) | 2020-11-18 |
| DK3408265T3 (en) | 2020-06-02 |
| JP2019503390A (en) | 2019-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201806424TA (en) | Therapeutic compounds | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201809470RA (en) | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201807597UA (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201900904PA (en) | Methods for cross coupling | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201809172WA (en) | Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201804774YA (en) | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201804587QA (en) | Isoindole compounds | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
| SG11201909263XA (en) | Improvements in or relating to organic compounds |